跳至主要内容
临床试验/NCT02731664
NCT02731664已完成1 期

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 in Vitro

Uppsala University2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2012年9月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
Motility index (measure of contraction amplitude x duration; area for mmHg x sec)

研究概览

简要总结

The inhibitory effect of low dose GLP-1 is investigated on prandial motility of the stomach, duodenum and jejunum in vivo in humans. Supplementary in vitro studies on the mechanism of action of the GLP-1 inhibition of motility as carried out on muscle strips from the upper gastrointestinal tract in man.

详细描述

Twelve healthy volunteers will undergo antroduodenojejunal manometry. Baseline recording with infusion of saline for 1 hour is compared with infusion of GLP-1 0.7 and 1.2 pmol per kg minute for another 1 hour. Plasma GLP-1 and GLP-2 is measured by RIA. Responses to GLP-1 will be measured after food intake as prandial response to GLP-1. The outcome will be evaluated as change in motility index from baseline to meal-stimulated conditions and during influence of GLP-1. Further in vitro studies of gastrointestinal muscle strips, precontracted with bethanechol or electric field stimulation, are planned to investigate the response to GLP-1 or GLP-1 analogue ROSE-010. GLP-1 and GLP-2 receptor immunoreactivity is localized by immunohistochemistry. Receptor mediated mechanisms are studied with GLP-1 receptor blocker exendin(9-39)amide, nitro-monomethyl arginine to block nitric oxide synthase and tetrodotoxin to block sodium channels and nerve conduction.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers over 18 years of age.

排除标准

  • Any medical condition.
  • Any drug treatment.

研究组 & 干预措施

GLP-1

Experimental

Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute

干预措施: GLP-1 (Biological)

Control

Placebo Comparator

Intravenous saline

干预措施: Intravenous saline (Biological)

结局指标

主要结局

Motility index (measure of contraction amplitude x duration; area for mmHg x sec)

时间窗: 60 minutes

Inhibition of prandially increased motility index (motor activity in the antrum and upper small intestine).

次要结局

  • Presence of GLP-1 and GLP-2 receptors in gastric and small bowel tissue(1 day)
  • Smooth muscle relaxation induced by GLP-1(6 hours)

研究者

发起方
Uppsala University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Per Hellström

Professor

Uppsala University

研究点 (2)

Loading locations...

相似试验

GLP-1 Inhibits Prandial Antro-duodeno-jejunal... | 临床试验